

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)



(10) International Publication Number
WO 2022/120131 A1

(51) International Patent Classification:

A61K 31/593 (2006.01) *A61P 17/06* (2006.01)
A61K 9/00 (2006.01) *A61P 17/10* (2006.01)
A61K 45/06 (2006.01) *A61P 17/14* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)
A61P 17/00 (2006.01) *A61P 37/06* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2021/061744

(22) International Filing Date:

03 December 2021 (03.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/121,531 04 December 2020 (04.12.2020) US
63/199,876 29 January 2021 (29.01.2021) US

(71) Applicant: **INCYTE CORPORATION** [US/US]; 1801
Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: **SMITH, Paul**; 1801 Augustine Cut-Off, Wilm-
ington, 19803 (US). **ZHANG, Zheng**; 1801 Augustine Cut-
Off, Wilmington, 19803 (US). **PARKER, Melissa**; 1801
Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(74) Agent: **BURGY, Adriana L.**; Finnegan, Henderson,
Farabow, Garrett & Dunner, LLP, 901 New York Avenue,
NW, Washington, D C. 20001-4413 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES

(57) Abstract: The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steato-cystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

WO 2022/120131 A1